TITLE:
Semaglutide’s Trail of Success in Weight Loss Management and HbA1c Reduction: A Systematic Review
AUTHORS:
Shayne Q. Paff, Mariam Sahibzada, Jacqueline Olivo
KEYWORDS:
Preventive Care, Obesity Management, Diabetes Management, Chronic Disease, Adjunct Therapy, Weight Loss Management
JOURNAL NAME:
Health,
Vol.15 No.10,
October
23,
2023
ABSTRACT: Introduction: Obesity is a preventable health condition, yet it remains a complex relapsing
global health conundrum, triggering an array of comorbidities, including
diabetes, dyslipidemia, hypertension, and mental health decline. This review
intends to highlight the success of semaglutide for its therapeutic
intervention for weight loss management in diabetics and non-diabetics and
HbA1c reduction in type 2 diabetics. Methods: We searched and
systematically reviewed the literature from within the past ten years on semaglutide
utilization for weight loss and HbA1c reduction. Databases investigated
included PMC, JAMA, Nature Medicine, and The Lancet, resulting in four original
research articles that were systematically reviewed. Web consultations with
WHO, CDC, and Healthy People 2030 were conducted to ascertain epidemiological
obesity and diabetes data. AAFP and USPSTF references were included for obesity
management and preventive care guidelines. Results: Based on results
from systematically reviewing four original research studies, semaglutide can
effectively reduce elevated weight and HbA1c, using the once-weekly
subcutaneous injection formulation. A composite average percent weight loss of
8.27% (16 - 20 pounds) and an average HbA1c percent reduction
rate of 1.07% (3 - 4
points) were attained. There were no major adverse events reported from any of
the four original research studies related to the drug. Discussion: With
evidence from several studies after its FDA approval, semaglutide delivers a
promise for weight loss management and HbA1c reduction for appropriate patient
populations. Clinician and patient education on its proper use should be
continuously revisited.